BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE:TGX), a medical device company serving the prostate cancer treatment and surgical markets, today announced consolidated financial results for the second quarter and six months ended July 1, 2007. Consolidated revenue for the quarter was $15.6 million compared to $12.6 million in the second quarter of 2006, an increase of 24%. For the six-month period, consolidated revenue was $31.0 million, compared to $25.0 million in the 2006 period, also an increase of 24%. Net income for the quarter was $1.5 million, or $0.05 per share, compared to net income of $433,000, or $0.01 per share in the second quarter of 2006. For the six-month period, net income was $2.7 million, or $0.08 per share, compared to net income of $1.2 million, or $0.04 per share, in 2006.
